U.S. Markets closed
  • S&P 500

    3,768.25
    -27.29 (-0.72%)
     
  • Dow 30

    30,814.26
    -177.24 (-0.57%)
     
  • Nasdaq

    12,998.50
    -114.10 (-0.87%)
     
  • Russell 2000

    2,123.20
    -32.15 (-1.49%)
     
  • Crude Oil

    51.96
    -0.40 (-0.76%)
     
  • Gold

    1,833.70
    +3.80 (+0.21%)
     
  • Silver

    25.01
    +0.14 (+0.58%)
     
  • EUR/USD

    1.2083
    -0.0001 (-0.0121%)
     
  • 10-Yr Bond

    1.0970
    -0.0320 (-2.83%)
     
  • Vix

    24.34
    +1.09 (+4.69%)
     
  • GBP/USD

    1.3540
    -0.0044 (-0.3209%)
     
  • USD/JPY

    103.7420
    -0.0580 (-0.0559%)
     
  • BTC-USD

    36,201.55
    +142.67 (+0.40%)
     
  • CMC Crypto 200

    702.42
    -32.72 (-4.45%)
     
  • FTSE 100

    6,735.05
    -0.66 (-0.01%)
     
  • Nikkei 225

    28,242.21
    -276.97 (-0.97%)
     

ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2020 Operating Results

·1 min read

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, November 6, 2020 to discuss its third quarter operating results. Management will also provide a brief update on the business.

Conference Call Information

To access the live call by phone, dial (877) 621-5803; the conference ID is 9864218. The call may also be accessed through the Investors and Media section of the Company’s website, www.immunogen.com. Following the call, a replay will be available at the same location.

ABOUT IMMUNOGEN

ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to "target a better now."

Learn more about who we are, what we do, and how we do it at www.immunogen.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201022005118/en/

Contacts

INVESTOR RELATIONS AND MEDIA

ImmunoGen
Courtney O’Konek
781-895-0600
courtney.okonek@immunogen.com

OR

FTI Consulting
Robert Stanislaro
212-850-5657
robert.stanislaro@fticonsulting.com